BioSpace News Archive

The latest market analysis report published by Reports and Data, titled ‘Global Polycythemia Market – Forecast to 2030,’ thoroughly examines the Polycythemia industry to provide essential data & information for the targeted readers.

Nutex Health Inc. announced that two of its micro hospitals, Alexandria Emergency Hospital and Tucson ER & Hospital, have won regional awards.

Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that Lumos Pharma management will participate in a panel discussion and host one-on-one meetings at the Cantor Neurology & Psychiatry Conference in October.

ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced that it will release its financial results for the third quarter 2022 after the market closes on Wednesday, November 2, 2022.

Renovacor, Inc. (NYSE: RCOR) today announced that preclinical studies characterizing the progression of cardiac dysfunction and mortality in a BAG3 haploinsufficiency mouse model of dilated cardiomyopathy will be featured in an upcoming poster presentation at Keystone Symposia’s Heart Failure: Mechanisms and Therapies Conference.

Telix Pharmaceuticals Limited and GenesisCare today announce that a first patient has been enrolled in the Phase II ProstACT TARGET study of Telix’s prostate cancer antibody therapy candidate TLX591 (177Lu-DOTA-rosopatamab), in patients experiencing a first recurrence of prostate-specific antigen (PSA) after initial therapy for prostate cancer.

AnPac Bio-Medical Science Co., Ltd. announced that on September 26, 2022, the Company and a group of nine institutional and individual investors have signed legally binding agreements for the investment in the Company by the Investors of approximately $3.67 Million.

Exicure, Inc. (NASDAQ: XCUR) today announced plans to restructure the Company and align resources to continue exploring strategic alternatives that maximize stockholder value.

TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the Jefferies Cell & Genetic Medicine Summit on Thursday, September 29 at 2:00PM E.T.

Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today announced that its board of directors has approved the grant of incentive stock options (the “Options”) to certain directors and officers to acquire an aggregate of 1,425,000 common shares.